Functional evaluation of novel soluble insulin-like growth factor (IGF)-II–specific ligand traps based on modified domain 11 of the human IGF2 receptor
Open Access
- 1 February 2007
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 6 (2) , 607-617
Abstract
Ligands transported by the mannose 6-phosphate/insulin-like growth factor (IGF)-II receptor (IGF2R) include IGF-II– and mannose 6-phosphate–modified proteins. Increased extracellular supply of IGF-II, either secondary to loss of the clearance function of IGF2R, loss of IGF binding protein function, or increased IGF2 gene expression, can lead to embryonic overgrowth and cancer promotion. Reduced supply of IGF-II is detrimental to tumor growth, and this suggests that gain of function of IGF-II is a molecular target for human cancer therapy. Domain 11 of IGF2R binds IGF-II with high specificity and affinity. Mutagenesis studies have shown that substitution of glutamic acid for lysine at residue 1554 results in a 6-fold higher affinity for IGF-II (20.5 nmol/L) than native domain 11 (119 nmol/L). Here, we generate a novel high-affinity IGF-II ligand trap by fusion of mutated human 11E1554K to a COOH-terminal human IgG1 Fc domain (11E1554K-Fc). The resulting homodimer has a significantly increased affinity for IGF-II (1.79 nmol/L) when measured by surface plasmon resonance. IGF-II signaling via the IGF-I receptor and the proliferative effect of IGF-II were specifically inhibited by 11E1554K-Fc in both HaCaT and Igf2−/− mouse embryonic fibroblast cells. These data confirm that a novel engineered and soluble IGF2R-11E1554K-Fc protein functions as an IGF-II–specific and high-affinity ligand trap in vitro and that this protein has potential application as an IGF-II antagonist for cancer therapy following in vivo experimental evaluation. [Mol Cancer Ther 2007;6(2):607–17]Keywords
This publication has 69 references indexed in Scilit:
- Kinetics of Insulin-like Growth Factor II (IGF-II) Interaction with Domain 11 of the Human IGF-II/Mannose 6-phosphate Receptor: Function of CD and AB Loop Solvent-exposed ResiduesJournal of Molecular Biology, 2006
- The Role of the M6P/IGF-II Receptor in Cancer: Tumor Suppression or Garbage Disposal?Hormone and Metabolic Research, 2004
- Vascular Endothelial Growth Factor-Trap Suppresses Tumorigenicity of Multiple Pancreatic Cancer Cell LinesClinical Cancer Research, 2004
- Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal developmentDevelopment, 2004
- Insulin/Insulin-like Growth Factor I Hybrid Receptors Have Different Biological Characteristics Depending on the Insulin Receptor Isoform InvolvedJournal of Biological Chemistry, 2002
- Real Time Kinetics of Insulin-like Growth Factor II (IGF-II) Interaction with the IGF-II/Mannose 6-Phosphate ReceptorJournal of Biological Chemistry, 2001
- An Insulin-Like Growth Factor II (IGF-II) Affinity-Enhancing Domain Localized within Extracytoplasmic Repeat 13 of the IGF-II/Mannose 6-Phosphate ReceptorMolecular Endocrinology, 1998
- A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesisNature, 1994
- Role of insulin-like growth factors in embryonic and postnatal growthCell, 1993
- In vitro paracrine regulation of human keratinocyte growth by fibroblast‐derived insulin‐like growth factorsJournal of Cellular Physiology, 1992